Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quisinostat + Paclitaxel/Carboplatin in Platinum-Resistant Ovarian Cancer
NCT02948075Phase 2Completed
- Sponsor
- NewVac
- Start
- Sep 2015
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of quisinostat in ovarian cancer, sponsored by NewVac. Primary endpoint: Objective Response Rate. Started Sep 2015; status: completed.
02
Drugs
quisinostat
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT02948075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02948075.